Compare AXTI & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXTI | XNCR |
|---|---|---|
| Founded | 1986 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 881.9M |
| IPO Year | 1998 | 2013 |
| Metric | AXTI | XNCR |
|---|---|---|
| Price | $24.21 | $11.56 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $11.05 | ★ $22.78 |
| AVG Volume (30 Days) | ★ 7.0M | 541.0K |
| Earning Date | 02-19-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $90,390,000.00 | ★ $150,132,000.00 |
| Revenue This Year | N/A | $18.68 |
| Revenue Next Year | $33.52 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 38.16 |
| 52 Week Low | $1.13 | $6.92 |
| 52 Week High | $28.65 | $18.69 |
| Indicator | AXTI | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 57.47 | 41.40 |
| Support Level | $23.60 | $11.25 |
| Resistance Level | $28.65 | $12.73 |
| Average True Range (ATR) | 3.25 | 0.78 |
| MACD | 0.43 | 0.08 |
| Stochastic Oscillator | 66.86 | 38.33 |
AXT Inc is a developer and producer of compound and single element semiconductor substrates, also known as wafers. The dominant substrates used in producing semiconductor chips and other electronic circuits are made from silicon. It is engaged in the design, development, manufacture, and distribution of high-performance compound semiconductor substrates and the sale of materials. The company provides alternative or specialty materials in the form of substrates or wafers, including compound and single-element substrates. Its compound substrates combine indium with phosphorous or gallium with arsenic. Geographically firm has its business presence across the region of Europe, Japan, Taiwan, China, North America, and the Asia Pacific from which China derives its maximum revenue to the company.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.